I recently visited Washington, D.C., and it was cold — perhaps not by the standards of northern states, but bitter compared with my home in South Florida. Now, I’ve been colder in my life, but the ...

Alzheimer’s disease is characterized by the protein plaques and tangles that are thought to be responsible for cell death and tissue loss in the brain. Tangles are twisted fibers of a protein called ...

As a former caregiver to an elderly parent who had Alzheimer’s disease, Florida-based Ray counts it a privilege to write columns discussing the day-to-day challenges associated with the onslaught of ...

Alzheimer’s disease is a progressive neurodegenerative disorder that is characterized by declining mental abilities that affect memory, cognitive function, and personality. It is the most common cause ...

Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...

Alzheimer’s disease is the most common type of dementia among older people. Its exact cause remains unknown, but may stem from a combination of environmental factors, lifestyle and genetics. Alzheimer ...

People who develop Alzheimer’s disease before age 65 are said to have “early-onset” or “young-onset” disease. Overall, about 5-6% of Alzheimer’s patients have early-onset disease. Alzheimer’s is a ...

Alzheimer’s disease (AD) is an irreversible and progressive neurological disorder, and the most common type of dementia. It is caused by damage to the brain and often first appears as minor changes in ...

Agitation is reported in about 50% of patients with Alzheimer’s disease. Aggressive behavior, irritability, disinhibition, and emotional distress are some of the features of agitation. The cause of ...

One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of so-called beta-amyloid fragments that stick together and accumulate ...

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for ...